BioAge Labs Inc. (BIOA)
BIOA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1709941/000119312526120873/0001193125-26-120873-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | BIOA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2024 |
| SEC CIK | 0001709941 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $9.0M |
| Net income | -$80.6M |
| Operating income | -$92.8M |
| Net margin | -896.1% |
| Operating margin | -1031.5% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $188.9M |
| Total assets | $294.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 26.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $52.7M cash; operating cash flow -$25.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 45,958,509 (2026-10-30); 35,855,037 a year earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-01-22 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, San Francisco, California, United States | PCAOB Form AP 2026-04-20 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $7.8M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $298K | -$33.5M | -$31.0M | $52.7M | $0 | $8.6M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $2.5M | -$26.1M | -$19.3M | $74.0M | $0 | $10.4M | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $2.8M | -$22.3M | -$24.0M | $241.8M | $1.2M | $10.3M | 10-Q 2026-05-08 |
| Q4 2025 2025-12-31 | $3.1M | -$25.9M | -$28.3M | $188.9M | $2.6M | $9.0M | 10-K 2026-03-24 |
| Q3 2025 2025-09-30 | $2.1M | -$20.2M | -$16.0M | $215.6M | $4.1M | $5.9M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $2.4M | -$21.6M | -$20.0M | $220.3M | $5.6M | $3.9M | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $1.5M | -$12.9M | -$17.4M | $257.5M | $7.1M | $1.5M | 10-Q 2026-05-08 |
| Q4 2024 2024-12-31 | $0 | -$21.1M | -$5.1M | $354.3M | $8.5M | $0 | 10-K 2026-03-24 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-03-24 |
| Latest annual report | 10-K | 2026-03-24 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-21 |
Source: SEC EDGAR submissions feed, 158 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.9% |
| 1 month | -0.4% |
| 3 months | -46.8% |
| Year to date | -58.0% |
| 1 year | -28.1% |
| From 52-week high | -77.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| FTH | Faeth Therapeutics Inc. | $9.28 | -7.48% | $239.8M |
| ARCT | Arcturus Therapeutics Holdings Inc. | $8.31 | -0.60% | $239.5M |
| RCKT | Rocket Pharmaceuticals Inc. | $2.16 | -6.09% | $241.2M |
| CAMP | CAMP4 Therapeutics Corporation | $3.86 | +1.58% | $242.2M |
| LFCR | Lifecore Biomedical Inc. | $6.42 | -0.08% | $243.2M |
| AMRN | Amarin Corporation plc | $11.31 | -0.62% | $233.4M |
| QTTB | Q32 Bio Inc. | $8.29 | -4.82% | $248.1M |
| VNDA | Vanda Pharmaceuticals Inc. | $3.81 | -4.51% | $230.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier